MFC Co Ltd
432980
Company Profile
Business description
MFC Co Ltd is engaged in the development and manufacturing of raw pharmaceutical ingredients or materials. The company utilizes basic technologies such as organic synthesis and mass production technology, new crystallization technology to develop and mass-produce active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials (Pharmaceutical Ingredients (PI)) for production.
Contact
35, Cheongwon Industrial Complex 7-gil
Mado-myeon, 1453 Cheongwon-ri
Hwaseong-si
Gyeonggi-do
Seoul
KORT: +82 3180598293
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
70
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,040.10 | 87.10 | -0.95% |
| CAC 40 | 7,654.25 | 53.65 | -0.70% |
| DAX 40 | 23,487.33 | 550.00 | -2.29% |
| Dow JONES (US) | 45,295.81 | 249.07 | -0.55% |
| FTSE 100 | 9,116.69 | 79.65 | -0.87% |
| HKSE | 25,381.57 | 114.98 | -0.45% |
| NASDAQ | 21,279.63 | 175.92 | -0.82% |
| Nikkei 225 | 42,035.72 | 274.77 | -0.65% |
| NZX 50 Index | 13,049.69 | 83.47 | -0.64% |
| S&P 500 | 6,415.54 | 44.72 | -0.69% |
| S&P/ASX 200 | 8,768.10 | 90.90 | -1.03% |
| SSE Composite Index | 3,820.98 | 37.15 | -0.96% |